STLN Starling Oncology, Inc.

QT79

NASDAQ·Healthcare·Medical - Care Facilities·USA

Latest market price

6.35

+0.13+2.09%

Overview Short InterestFilings

STLNQT79Starling Oncology, Inc.·NASDAQ

Overview Short InterestFilings

6.35+2.09%

News

Up 2.1% — Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation (Yahoo).

Medium confidence

Loading chart...

Screen all →

GMRS+4.99%$9.89 SRTA-2.07%$4.73 CYH-1.09%$2.72 AUNA+1.61%$5.06 VMD+0.55%$9.13 INNV+1.82%$8.96 USPH+1.36%$83.72 PNTG+1.16%$39.24

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.30	Insider Own	-	Shs Outstand	99.98M	Perf Week	-4.45%

Market Cap	621.89M	Forward P/E	-	EPS next Y	-0.02	Insider Trans	-	Shs Float	86.67M	Perf Month	4.71%

Enterprise Value	677.89M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-

Income	-37.00M	P/S	1.06	EPS this Y	45.83%	Inst Trans	-	Short Ratio	-	Perf Half Y	-

Sales	587.00M	P/B	-	EPS next Y	84.62%	ROA	-20.36%	Short Interest	-	Perf YTD	18.70%

Book/sh	-0.25	P/C	15.17	EPS next 5Y	-	ROE	209.81%	52W High	7.28 -12.76%	Perf Year	-

Cash/sh	0.41	P/FCF	-	EPS past 3/5Y	-	ROIC	-28.82%	52W Low	4.95 28.25%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	15.69%	Volatility	5.11% 5.71%	Perf 5Y	-

Dividend TTM	-	EV/Sales	1.15	EPS Y/Y TTM	-	Oper. Margin	-4.44%	ATR (14)	0.38	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.15	Sales Y/Y TTM	-	Profit Margin	-6.18%	RSI (14)	45.98	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	1.36	EPS Q/Q	52.94%	SMA20	-3.90%	Beta	1.44	Target Price	-

Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	-1.14%	Rel Volume	0.69	Prev Close	6.22

Employees	641	LT Debt/Eq	-6.00	Earnings	-	SMA200	-1.14%	Avg Volume	1.44M	Price	6.35

IPO Date	Aug 04, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-25.00% 3.56%	Net Debt/EBITDA	-2.90	Volume	994,200	Change	2.09%

Latest News· Times ET

Oct-01-26

Oct-01-2604:14PM

Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference ParticipationYahoo

Sep-30-26

Sep-30-2605:32AM

Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Ratingseekingalpha.com

Company

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025
Total Revenue	587	503
Cost of Goods Sold Incl. D&A	495	426
Gross Profit	92	76
Selling, General and Administrative Excl. Other	111	106
Research and Development	0	0
Other Operating Expense	8	7
Operating Income	-27	-36
Interest Expense	8	11
Unusual Expense	—	—
Non-Operating Income (Expense)	-3	-13
Net Income Before Taxes	-37	-61
Income Taxes	0	0
Consolidated Net Income	-37	-61
Net Income From Continuing Operations	-37	-61
Net Income	-37	-61
EPS (Recurring)	-0.30	-0.54
EPS (Basic, Before Extraordinaries)	-0.30	-0.54
EPS (Diluted)	-0.30	-0.54
EBITDA	-22	-43
Other After Tax Adjustments	—	—
Stock Option Compensation Expense	—	—
Price To Earnings Ratio	—	—
Price To Sales Ratio	1.11	0.65
Gross Margin	15.67	15.11
Operating Margin	-4.60	-7.16
Net Margin	-6.30	-12.13
Shares Outstanding	103	92
Market Capitalization	654	328
Operating Lease Expense	—	—

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.